DE10045621A1 - Treating hepatitis B and C comprises administration of prothymosin alpha - Google Patents
Treating hepatitis B and C comprises administration of prothymosin alphaInfo
- Publication number
- DE10045621A1 DE10045621A1 DE10045621A DE10045621A DE10045621A1 DE 10045621 A1 DE10045621 A1 DE 10045621A1 DE 10045621 A DE10045621 A DE 10045621A DE 10045621 A DE10045621 A DE 10045621A DE 10045621 A1 DE10045621 A1 DE 10045621A1
- Authority
- DE
- Germany
- Prior art keywords
- prothymosin
- hepatitis
- comprises administration
- treating hepatitis
- prothymosin alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
Abstract
Description
Die Erfindung betrifft die Behandlung von Hepatitis in den Formen B oder C.The invention relates to the treatment of hepatitis in forms B or C.
Die medikamentöse Therapie von Lebererkrankungen, wie Hepatitis B oder C, ist bisher nur in bescheidenem Umfang möglich. Die früher vorgeschlagenen Be handlungen mit hohen Vitamindosen oder sogenannten Lipotropenstoffen, wie z. B. Cholin oder Methionin, können Lebererkrankungen nur dann günstig beein flussen, wenn diese Stoffe nicht in ausreichender Menge mit der Nahrung zuge führt werden, was aber nur selten zutrifft. Die Wirkung zahlreicher pflanzlicher Kombinationspräparate ist nicht belegt und umstritten. In schweren Fällen des Krankheitsverlaufs wird eine kurzfristige, hoch dosierte Gabe von Glucocorticoi den, vorgenommen, die jedoch erhebliche Nebenwirkungen mit sich bringt. Zu meist werden gleichzeitig auch Immunsuppressiva (insbesondere Azathioprin) gegeben. Drug therapy for liver diseases such as hepatitis B or C is so far only possible on a modest scale. The previously proposed Be acts with high doses of vitamins or so-called lipotropic substances, such as z. B. choline or methionine, can only affect liver diseases favorably flow when these substances are not in sufficient quantities with the food are carried out, which is rarely the case. The effect of numerous herbal Combination drugs have not been proven and are controversial. In severe cases of The course of the disease is a short-term, high-dose administration of Glucocorticoi which, however, has significant side effects. to mostly immunosuppressive drugs (especially azathioprine) given.
Es besteht daher ein erheblicher Bedarf an einer medikamentösen Behandlung von Hepatitis B oder C mit Wirkstoffen, die die Bekämpfung der die Hepatitis auslösenden Viren B und C ermöglichen.There is therefore a significant need for drug treatment of hepatitis B or C with active ingredients that fight the hepatitis enable triggering viruses B and C.
Erfindungsgemäß wurde gefunden, das Prothymosin α eine erfolgreiche medika mentöse Therapie für Hepatitis B und C ermöglicht.According to the invention, the prothymosin α was found to be a successful medication mental therapy for hepatitis B and C enables.
Prothymosin α ist ein biologisches Polypeptidhormon, das etwa 107 bis 113 Aminosäurereste aufweist und in US 4,659,694 und US 4,716,148 ausführlich beschrieben ist. Prothymosin α ist als immunpotenzierender Wirkstoff bekannt.Prothymosin α is a biological polypeptide hormone that is approximately 107 to 113 Has amino acid residues and in detail in US 4,659,694 and US 4,716,148 is described. Prothymosin α is known as an immunopotentiating agent.
Überraschend ist gefunden worden, dass Prothymosin α zur Bekämpfung von Hepatitis B und C geeignet ist, wobei die Wirkung von Prothymosin α nicht auf einer Immunverstärkung beruht, die bei Hepatitiserkrankungen regelmäßig auch gar nicht angestrebt wird (vgl. die Verabreichung von Immunsuppressiva), son dern auf einer direkten Beeinflussung der infizierten Hepatocyten beruht. Diese Wirkung von Prothymosin α ist überraschend und war nicht vorhersehbar.Surprisingly, it has been found that prothymosin α is used to combat Hepatitis B and C is suitable, but the effect of prothymosin α is not an immune boost that is also regular in hepatitis diseases is not at all desired (cf. the administration of immunosuppressants), son which is based on a direct influence on the infected hepatocytes. This The effect of prothymosin α is surprising and was not predictable.
In einem in vitro Test lässt sich eine direkt durch Prothymosin α verursachte signifikante Abnahme der Replikation der Viren B und C in den infizierten Hepa tocyten feststellen. Der Test konnte des Weiteren bei einer potenzierenden Do sierung von Prothymosin α die Reduktion bzw. Eliminierung der Hepatitisviren in der Zellkultur nachweisen.In an in vitro test, one can be caused directly by prothymosin α significant decrease in replication of viruses B and C in the infected Hepa detect tocytes. The test was also successful in a potentiating Do sation of prothymosin α the reduction or elimination of the hepatitis viruses in detect the cell culture.
Nachfolgend sind zwei Behandlungsbeispiele aufgeführt:Two treatment examples are listed below:
Patientin, 49 Jahre, seit 1½ Jahren an Hepatitis B erkrankt. Nach langer und systematischer potenzierender Behandlung von 2× wöchentlich 5 bis 20 mg Pro thymosin α zeigte sich innerhalb von 6 Monaten Therapiedauer eine eindeutige Verringerung der Viren bis hin zur Nachweisbarkeitsgrenze sowie eine Serum konversion. Patient, 49 years old, had hepatitis B for 1½ years. After a long and systematic potentiating treatment of 5 to 20 mg Pro twice a week thymosin α was clearly evident within 6 months of therapy Reduction of viruses up to the detectability limit as well as a serum conversion.
Patientin, 74 Jahre, seit 2½ Jahren an Hepatitis C erkrankt. Nach einjähriger potenzierender Behandlung mit 2× wöchentlich 5 bis 20 mg Prothymosin α wur de eine Serumkonversion festgestellt und der Hepatitisvirus C war reduziert bzw. konnte nicht mehr nachgewiesen werden.Patient, 74 years old, had hepatitis C for 2½ years. After one year potentiating treatment with twice a week 5 to 20 mg prothymosin α wur en a serum conversion was found and the hepatitis virus C was reduced or could no longer be proven.
Die Bekämpfung der Hepatitisviren B und C durch Prothymosin α, wie sie im in vitro Test festgestellt wurde, konnte somit durch klinische Erfahrungen bestätigt werden.The fight against hepatitis viruses B and C by prothymosin α, as in vitro test was determined, could thus be confirmed by clinical experience become.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10045621A DE10045621A1 (en) | 2000-09-15 | 2000-09-15 | Treating hepatitis B and C comprises administration of prothymosin alpha |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10045621A DE10045621A1 (en) | 2000-09-15 | 2000-09-15 | Treating hepatitis B and C comprises administration of prothymosin alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10045621A1 true DE10045621A1 (en) | 2002-04-04 |
Family
ID=7656286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10045621A Withdrawn DE10045621A1 (en) | 2000-09-15 | 2000-09-15 | Treating hepatitis B and C comprises administration of prothymosin alpha |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE10045621A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754687B2 (en) * | 2005-02-24 | 2010-07-13 | Mount Sinai School Of Medicine | Methods of inhibiting viral infection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4716148A (en) * | 1984-08-13 | 1987-12-29 | Hoffman-La Roche Inc. | Prothymosin alpha |
| US6106868A (en) * | 1990-08-24 | 2000-08-22 | The Board Of Governors Of Wayne State University | Method for the treatment of hepatitis |
-
2000
- 2000-09-15 DE DE10045621A patent/DE10045621A1/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4716148A (en) * | 1984-08-13 | 1987-12-29 | Hoffman-La Roche Inc. | Prothymosin alpha |
| US6106868A (en) * | 1990-08-24 | 2000-08-22 | The Board Of Governors Of Wayne State University | Method for the treatment of hepatitis |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754687B2 (en) * | 2005-02-24 | 2010-07-13 | Mount Sinai School Of Medicine | Methods of inhibiting viral infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69927971T2 (en) | USE OF PEG-IFN-ALPHA AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C | |
| Mahmoud et al. | Anti-inflammatory effects of tartar emetic and niridazole: suppression of schistosome egg granuloma | |
| CN109906077B (en) | Sublingual pharmaceutical composition of edaravone and (+) -2-borneol | |
| EP3031456A1 (en) | Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof | |
| AU2018357350B2 (en) | Delayed release deferiprone tablets and methods of using the same | |
| DE69929330T2 (en) | NEW USE OF HIV PROTEASE INHIBITORS | |
| CN111419800B (en) | Medicinal preparation for treating lupus erythematosus and preparation method thereof | |
| DE69534039T2 (en) | USE OF VALIN FOR THE MANUFACTURE OF A MEDICAMENT FOR LIVER REGENERATION | |
| DE19547317A1 (en) | Antiviral drug | |
| DE10045621A1 (en) | Treating hepatitis B and C comprises administration of prothymosin alpha | |
| WO2012104355A1 (en) | Antiviral agent containing recombinant mistletoe lectins | |
| DE4413938A1 (en) | Peptides as a therapeutic agent for autoimmune diseases | |
| WO2005041994A1 (en) | Use of prickly pear (opuntia) plant parts and/or extracts for the treatment of depressions | |
| DE69631768T2 (en) | USE OF L-CARNITINE AND DERIVATIVES FOR REDUCING THE CERAMID MIRROR AND PROMOTING THE EFFECT OF ANTIRETROVIRAL AGENTS | |
| DE2250032C3 (en) | Medicines based on lysine derivatives to combat leukopenia and normalize the percentage composition of the leukocyte picture | |
| Belo et al. | Gastroprotective effects of oral nucleotide administration | |
| WO2018228430A1 (en) | Use of isoferulic acid, isoferulic acid-containing traditional chinese medicine extract and cimicifugae foetidae | |
| DE69925900T2 (en) | Prophylactics and remedies for disorders of the intestinal mucosa | |
| JPH10158183A (en) | Composition for preventing and treating hangover | |
| DE60005188T2 (en) | GRF-CONTAINING LYOPHILIZED COMPOSITIONS | |
| CN112168827A (en) | A pharmaceutical composition for treating psoriasis and preparation method thereof | |
| DE202015003548U1 (en) | Whole egg preparation | |
| DE69332982T2 (en) | COMPOSITIONS CONTAINING THYMOSIN-ALPHA-1 FOR TREATING HEPATITIS B IN PATIENTS WITH DECOMPENSED LIVER DISEASE | |
| WO2022053108A1 (en) | Glucocorticoid for use in the prophylaxis of an ards | |
| KR20220037979A (en) | Pharmaceutical composition comprising aqueous solubilized bile acid for the prevention or treatment of sepsis, acute lung injury disease, or acute respiratory distress syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8180 | Miscellaneous part 1 |
Free format text: DER 1. ANMELDER IST ZU AENDERN IN: PESIC, MILAN C., DR.MED., 38667 BAD HARZBURG, DE |
|
| 8130 | Withdrawal |